Natural Product (NP) Details
General Information of the NP (ID: NP5233) | |||||
---|---|---|---|---|---|
Name |
Wogonin
|
||||
Synonyms |
5,7-Dihydroxy-8-methoxyflavone; Vogonin; Norwogonin 8-methyl ether; UNII-POK93PO28W; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; BRN 0287152; POK93PO28W; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; CHEMBL16171; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; CHEBI:10043; XLTFNNCXVBYBSX-UHFFFAOYSA-N; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; ST077088; Q-100730; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one; 632-85-9
Click to Show/Hide
|
||||
Species Origin | Arachis hypogaea ... | Click to Show/Hide | |||
Arachis hypogaea | |||||
Physalis minima | |||||
Anodendron affine | |||||
Scutellaria amoena | |||||
Disease | Hepatocellular carcinoma [ICD-11: 2C12] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C16H12O5
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O
|
||||
InChI |
1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3
|
||||
InChIKey |
XLTFNNCXVBYBSX-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 632-85-9
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | ULK1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Peroxynitrite formation | ||||
In-vitro Model | BGC-823 | CVCL_3360 | Gastric cancer | Homo sapiens | ||
In-vivo Model | Approximately 300 cells for the CM-Dil-labeled BGC-823 cells were injected into the yolk sac per zebrafish embryo using a microinjector. | |||||
Experimental
Result(s) |
Wogonin exacerbates the cytotoxic effect of oxaliplatin by inducing nitrosative stress and autophagy in human gastric cancer cells. | |||||
Tumor necrosis factor alpha | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
|
Biological
Regulation |
Neutralization | TNFAlpha-induced free radical O2- | ||||
In-vitro Model | ARAC-8C | CVCL_GZ09 | T acute lymphoblastic leukemia | Homo sapiens | ||
Experimental
Result(s) |
Wogonin attenuates NF-kappaB activity by shifting TNFalpha-induced free radical .O(2)(-) to a more reduced nonradical product, H(2)O(2), and thereby sensitizes TNFalpha-resistant leukemia cells to TNFalpha-induced apoptosis. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MAGT1 | Molecule Info | |||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | A549 non-small-cell lung cancer cells (2*106) resuspended in 0.1mL of PBS were injected subcutaneously into six weeks old athymic (nu/nu) male nude mice. | |||||
Experimental
Result(s) |
Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins. | |||||
Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | IKKA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | Nude mice were inoculated subcutaneously with injections of 1*107 SMMC-7721 cells/mouse at the right axilla. | |||||
Experimental
Result(s) |
Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | IGF1R | Molecule Info |
Pathway MAP
|
||
In-vitro Model | BCaP-37 | CVCL_0164 | Breast cancer | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Wogonin increases doxorubicin sensitivity by down-regulation of IGF-1R/AKT signaling pathway in human breast cancer. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
ABT-263 | Chronic lymphocytic leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | ARAC-8C | CVCL_GZ09 | T acute lymphoblastic leukemia | Homo sapiens | ||
MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | |||
Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | |||
KM-H2 | CVCL_1330 | Hodgkin lymphoma | Homo sapiens | |||
In-vivo Model | Immunodeficient mice (Rag2-/-/II2rg-/-) were implanted subcutaneously in the dorsal flank region with CEM (5*107 cells). | |||||
Experimental
Result(s) |
Wogonin potentiates the lethality of ABT-263 in ABT-263-resistant cancer cells and wogonin reduces the effective dose of ABT-263 thereby possibly decreasing the risk of adverse side effects. | |||||
γ. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BBC3 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | GABPA | Molecule Info | |||
Down-regulation | Expression | GSTP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | ROS accumulation | ||||
In-vitro Model | AMC-HN-2 | CVCL_5960 | Squamous cell carcinoma | Homo sapiens | ||
AMC-HN-3 | CVCL_5961 | Laryngeal squamous cell carcinoma | Homo sapiens | |||
AMC-HN-4 | CVCL_5962 | Tongue squamous cell carcinoma | Homo sapiens | |||
AMC-HN-5 | CVCL_5963 | Nasal cavity squamous cell carcinoma | Homo sapiens | |||
AMC-HN-9 | CVCL_5967 | Mucoepidermoid carcinoma | Homo sapiens | |||
SNU-1041 | CVCL_L085 | Squamous cell carcinoma | Homo sapiens | |||
SNU-1066 | CVCL_5005 | Laryngeal squamous cell carcinoma | Homo sapiens | |||
SNU-1076 | CVCL_5006 | Laryngeal squamous cell carcinoma | Homo sapiens | |||
In-vivo Model | AMC-HN4-cisR or HN9-cisR cells (5*106) were injected subcutaneously into the flank of 6-week-old athymic BALB/c male nude mice (nu/nu). | |||||
Experimental
Result(s) |
Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Prostaglandin G/H synthase 2 (COX-2) | Molecule Info | [10] | |
Xanthine dehydrogenase/oxidase (XDH) | Molecule Info | [11] | ||
BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
2 | Aspirin triggered resolvin D biosynthesis | |||
3 | C20 prostanoid biosynthesis | |||
4 | Aspirin triggered resolvin E biosynthesis | |||
5 | Purine nucleotides degradation | |||
6 | Urate biosynthesis/inosine 5'-phosphate degradation | |||
7 | Guanosine nucleotides degradation | |||
8 | Adenosine nucleotides degradation | |||
9 | Retinoate biosynthesis II | |||
KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | NF-kappa B signaling pathway | |||
4 | VEGF signaling pathway | |||
5 | TNF signaling pathway | |||
6 | Retrograde endocannabinoid signaling | |||
7 | Serotonergic synapse | |||
8 | Ovarian steroidogenesis | |||
9 | Oxytocin signaling pathway | |||
10 | Regulation of lipolysis in adipocytes | |||
11 | Leishmaniasis | |||
12 | Pathways in cancer | |||
13 | Chemical carcinogenesis | |||
14 | MicroRNAs in cancer | |||
15 | Small cell lung cancer | |||
16 | Purine metabolism | |||
17 | Caffeine metabolism | |||
18 | Drug metabolism - other enzymes | |||
19 | Peroxisome | |||
NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
2 | TSH Signaling Pathway | |||
3 | IL4 Signaling Pathway | |||
4 | TGF_beta_Receptor Signaling Pathway | |||
5 | IL5 Signaling Pathway | |||
Panther Pathway | Endothelin signaling pathway | Click to Show/Hide | ||
2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
3 | Toll receptor signaling pathway | |||
4 | CCKR signaling map ST | |||
5 | Adenine and hypoxanthine salvage pathway | |||
6 | Purine metabolism | |||
Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
2 | Caffeine Metabolism | |||
3 | Purine Metabolism | |||
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | Click to Show/Hide | ||
2 | S1P1 pathway | |||
3 | C-MYB transcription factor network | |||
4 | Signaling mediated by p38-alpha and p38-beta | |||
5 | Calcium signaling in the CD4+ TCR pathway | |||
Reactome | Purine catabolism | Click to Show/Hide | ||
WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
2 | Arachidonic acid metabolism | |||
3 | Aryl Hydrocarbon Receptor | |||
4 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
5 | Spinal Cord Injury | |||
6 | Integrated Pancreatic Cancer Pathway | |||
7 | Eicosanoid Synthesis | |||
8 | Selenium Micronutrient Network | |||
9 | Oxidative Stress | |||
10 | Effects of Nitric Oxide | |||
11 | Metabolism of nucleotides |